A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
France, Denmark, Germany, Spain, Italy, Netherlands
Condition studied
Cardiovascular Disease
Investigational medicinal product(s)
Placebo for AMG 890Olpasiran
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
change in non-calcified plaque volume from baseline to week 72
Endpoint detail
change in the following volume types from baseline to week 72: -low attenuation plaque volume -total plaque volume -calcified plaque volume
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.